RFK Jr.’s $5 B Push to Link Vaccines and Autism: A Costly Misadventure

Since surfacing on the national stage alongside former President Donald Trump, Robert F. Kennedy Jr. has turned his long‑standing anti‑vaccine rhetoric into a headline policy point. What was once fringe commentary is now being floated as a multi‑billion‑dollar government initiative.

According to a group of 16 current and former health officials who spoke with Reuters on condition of anonymity, Kennedy approached Dr. Jay Bhattacharya, director of the National Institutes of Health, early this year with a startling proposal: allocate as much as $5 billion—roughly ten percent of the NIH’s yearly budget—to investigate whether vaccines cause autism.

That figure is staggering. It would dwarf the modest $1.6 million the Department of Health and Human Services already spent on a controversial study of hepatitis B vaccines led by Danish researchers Peter Aaby and Christine Stabell Benn. That earlier project raised eyebrows because it risked withholding life‑saving shots from newborns in Guinea‑Bissau, prompting the Africa Centres for Disease Control and Prevention to step in and halt it.

Experts are quick to point out that the scientific community has, for decades, demonstrated no causal link between any vaccine and autism. “He’s an anti‑vaccine activist. That’s who he is, and has been for twenty years,” said Dr. Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia. “To expect that as secretary of Health and Human Services he’d be anything other than that is wishful thinking.”

The proposed spending plan, if approved, would not just be a financial misstep; it would also echo some of the darkest chapters in medical history. Observers have drawn uncomfortable parallels to the Tuskegee Syphilis Study, where hundreds of Black men were denied treatment for decades in the name of research. While Kennedy’s plan may not be as overtly malicious, its reliance on discredited science could still jeopardize public trust and divert resources from genuine health priorities.

Critics argue that the $5 billion could be better spent on proven public‑health measures—such as expanding access to affordable care, bolstering pandemic preparedness, or addressing the rising rates of chronic disease. Instead, Kennedy appears intent on using the federal coffers to chase a phantom threat, a move that many view as a profound waste of taxpayer money.

As the debate unfolds, the question isn’t just about dollars. It’s about whether a democratic government should fund research that runs counter to a robust body of evidence, and whether the leadership of a future health department will be guided by data or ideology.